382 related articles for article (PubMed ID: 12599570)
1. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
2. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
[No Abstract] [Full Text] [Related]
3. [Antiandrogen in prostate cancer].
Maeda O; Usami M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
[No Abstract] [Full Text] [Related]
4. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
5. [Endocrine therapy for prostate cancer in the future].
Usami M
Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
7. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
8. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
Collette L; Studer UE; Schröder FH; Denis LJ; Sylvester RJ
Prostate; 2001 Jun; 48(1):29-39. PubMed ID: 11391684
[TBL] [Abstract][Full Text] [Related]
9. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
11. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
12. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
13. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
16. The place and the results of monotherapy.
Bonnet P
Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
[No Abstract] [Full Text] [Related]
17. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Crawford ED; Goodman P; Blumenstein B
Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
[No Abstract] [Full Text] [Related]
18. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
Kirby RS
Br J Clin Pract; 1996; 50(5):287. PubMed ID: 8794610
[No Abstract] [Full Text] [Related]
19. [Hormonal treatment of cancer of the prostate: review and present status].
Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
[No Abstract] [Full Text] [Related]
20. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
